Eyeing Enzalutamide for Hormone-Sensitive Prostate Cancer.
In men with metastatic hormone-sensitive prostate cancer, the androgen-receptor inhibitor enzalutamide prolonged radiographic progression-free survival more than a placebo did when given with androgen-deprivation therapy.